Citations

Mayo Clinic

Showing 10 of 108522 citations.

Genotype-Phenotype Correlations in Apical Variant Hypertrophic Cardiomyopathy
Towe, Eric, Bos, J. Martijn , Ommen, Steve R. , Ackerman, Michael J. , Towe, Eric C, Gersh, Bernard J. , Bos, Johan M

Congenital Heart Disease | December 15, 2014 | Volume: 10 | Issue: 3 | Pages: E139-E145

10.1111/chd.12242 | PMID 25495007 Get It

The prevalence of burning mouth syndrome: a population-based study
Kohorst, John J. , Bruce, A.J., Torgerson, Rochelle R. , Schenck, Louis A., Davis, Mark D.P.

British Journal of Dermatology | December 15, 2014 | Volume: 172 | Issue: 6 | Pages: 1654-1656

10.1111/bjd.13613 | PMID 25495557 Get It

Concomitant Septal Myectomy in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis
Lim, Ju Yong , Choi, Jin‐Oh , Oh, Jae K. , Park, Soon J., Oh, Jae K. , Li, Zhou

Circulation Journal | December 14, 2014 | Volume: 79 | Issue: 2 | Pages: 375-380

10.1253/circj.cj-14-0672 | PMID 25502166 Get It

Evaluation of Suspected Aspirated Beverage Can Pull Tab: Radiographs May Not Be Enough
Campeau, Norbert G. , Oeckler, Richard A. , Kotsenas, Amy L. , Kuzo, Ronald S. , Campeau, Norbert G

Case Reports in Radiology | December 14, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-3

10.1155/2014/196960 | PMID 25580344 Get It

A 67-year-old male presented to the emergency department with concern for accidental aspiration of an aluminum beverage can pull tab. Neck and chest radiographs did not reveal an aspirated foreign body. Despite ongoing complaint of dysgeusia and adamancy of aspiration by the patient, he was discharged to home without recommendation for further follow-up. Seven months later, a computed tomography (CT) scan of the chest performed as part of an unrelated lung cancer work up confirmed the presence of a left mainstem bronchus metallic foreign body compatible with a pull tab. This case report illustrates the poor negative predictive value of radiographs for a suspected aluminum foreign body and demonstrates the superiority of CT for this purpose. In such presentations it is imperative to have a low threshold for performing further diagnostic evaluation with CT due to the relatively high radiolucency of aluminum.
Retrospective Analysis of Interobserver Spatial Variability in the Localization of Broca's and Wernicke's Areas Using Three Different fMRI Language Paradigms
Black, David F. , DeLone, David R. , Fitz‐Gibbon, Patrick D., Carter, Rickey E. , Welker, Kirk M. , Fitz-Gibbon, Patrick D, Kaufmann, Timothy J. , Machulda, Mary M. , Carter, Rickey E

Journal of Neuroimaging | December 13, 2014 | Volume: 25 | Issue: 4 | Pages: 626-633

10.1111/jon.12179 | PMID 25496329 Get It

ABSTRACTPURPOSETo determine interobserver spatial variability in language area localization using three commonly employed language tasks.MATERIALS AND METHODSWith institutional review board approval, 125 fMRI time series from 50 different clinical language cases were retrospectively reviewed by three blinded readers who selected 3‐dimensional points representing the perceived center of Wernicke's and Broca's areas using three language tasks (semantic decision, SD; sentence comprehension, SC; and silent word generation, WG). Point dispersion values were then calculated using the perimeter of the 3‐dimensional triangle defined by the three readers’ selections.RESULTSAfter resolving interobserver laterality disagreements, there was no difference in spatial variability between the three tasks (P = .069). The SD task had the fewest interobserver laterality disagreements (P = .028) and the SC task had fewer failed localizations for Broca's area (P = .050) and Wernicke's area (P = .013).CONCLUSIONWhile there were no differences between interobserver spatial variability in language area localization between the three tasks, language task choice impacts the accuracy of fMRI language area identification because tasks vary in their rates of interobserver laterality disagreements and failed localizations. A combination of tasks including one with low laterality disagreements (eg, SD) and one with few failed localizations (eg, SC) may offer the best combination.
Recipient clinical risk factors predominate in possible transfusion‐related acute lung injury
Toy, Pearl, Bacchetti, Peter , Grimes, Barbara , Murphy, Edward L. , Gropper, Michael A. , Hubmayr, Rolf D., Matthay, Michael A. , Wilson, Gregory , Koenigsberg, Monique, Lee, Deanna C., Hirschler, Nora V., Lowell, Clifford A. , Schuller, Randy M. , Norris, Philip J. , Mair, David , Rosen, Rosa Sanchez, Looney, Mark R. , Winters, Jeffrey L. , Gajic, Ognjen , Gandhi, Manish J.

Transfusion | December 13, 2014 | Volume: 55 | Issue: 5 | Pages: 947-952

10.1111/trf.12954 | PMID 25488517 Get It

Background Possible transfusion‐related acute lung injury (p TRALI ) cases by definition have a clear temporal relationship to an alternative recipient risk factor for acute respiratory distress syndrome ( ARDS ). We questioned whether transfusion factors are important for the development of p TRALI . Study Design and Methods In this nested case‐control study, we prospectively identified 145 consecutive patients with p TRALI and randomly selected 163 transfused controls over a 4‐year period at the U niversity of C alifornia at S an F rancisco and the M ayo C linic ( R ochester, M innesota). Results For p TRALI , we found evidence against transfusion being important: receipt of plasma from female donors (odds ratio [ OR ], 0.82; 95% confidence interval [ CI ], 0.29‐2.3; p = 0.70), total number of units transfused ( OR , 0.99; 95% CI , 0.89‐1.10; p = 0.86), and number of red blood cell and whole blood units transfused ( OR , 0.78; 95% CI , 0.59‐1.03; p = 0.079). In contrast, we found that risk for p TRALI was associated with additional recipient factors: chronic alcohol abuse ( OR , 12.5; 95% CI , 2.8‐55; p < 0.001), current smoker ( OR , 4.2; 95% CI , 1.67‐10.8; p = 0.0024), shock before transfusion ( OR , 4.6; 95% CI , 2.0‐10.7; p < 0.001), and positive fluid balance before transfusion ( OR , 1.32/ L ; 95% CI , 1.20‐1.44; p < 0.001). Conclusion Recipient risk factors for ARDS rather than transfusion risk factors predominate in p TRALI .
Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients
Hellkamp, Anne S., Curtis, Lesley H. , Hammill, Stephen C., Masoudi, Frederick A. , Bhatt, Deepak L. , Al‐Khalidi, Hussein R. , Heidenreich, Paul A. , Anstrom, Kevin J. , Fonarow, Gregg C. , Pokorney, Sean D, Yancy, Clyde W. , Al-Khalidi, Hussein R, Al-Khatib, Sana M, Pokorney, Sean D. , Peterson, Eric D. , Al‐Khatib, Sana M. , Bhatt, Deepak L

Circulation: Arrhythmia and Electrophysiology | December 13, 2014 | Volume: 8 | Issue: 1 | Pages: 145-151

10.1161/circep.114.001878 | PMID 25504649 Get It

Background— Racial and ethnic minorities are under-represented in clinical trials of primary prevention implantable cardioverter-defibrillators (ICDs). This analysis investigates the association between primary prevention ICDs and mortality among Medicare, racial/ethnic minority patients. Methods and Results— Data from Get With The Guidelines-Heart Failure Registry and National Cardiovascular Data Registry’s ICD Registry were used to perform an adjusted comparative effectiveness analysis of primary prevention ICDs in Medicare, racial/ethnic minority patients (nonwhite race or Hispanic ethnicity). Mortality data were obtained from the Medicare denominator file. The relationship of ICD with survival was compared between minority and white non-Hispanic patients. Our analysis included 852 minority patients, 426 ICD and 426 matched non-ICD patients, and 2070 white non-Hispanic patients (1035 ICD and 1035 matched non-ICD patients). Median follow-up was 3.1 years. Median age was 73 years, and median ejection fraction was 23%. Adjusted 3-year mortality rates for minority ICD and non-ICD patients were 44.9% (95% confidence interval [CI], 44.2%–45.7%) and 54.3% (95% CI, 53.4%–55.1%), respectively (adjusted hazard ratio, 0.79; 95% CI, 0.63–0.98; P =0.034). White non-Hispanic patients receiving an ICD had lower adjusted 3-year mortality rates of 47.8% (95% CI, 47.3%–48.3%) compared with 57.3% (95% CI, 56.8%–57.9%) for those with no ICD (adjusted hazard ratio, 0.75; 95% CI, 0.67%–0.83%; P <0.0001). There was no significant interaction between race/ethnicity and lower mortality risk with ICD ( P =0.70). Conclusions— Primary prevention ICDs are associated with lower mortality in nonwhite and Hispanic patients, similar to that seen in white, non-Hispanic patients. These data support a similar approach to ICD patient selection, regardless of race or ethnicity.
Predicting Risk of Endovascular Device Infection in Patients With Staphylococcus aureus Bacteremia (PREDICT-SAB)
Sohail, M. Rizwan , Palraj, Bharath Raj, Uslan, Daniel Z. , Al‐Saffar, Farah , Friedman, Paul A. , Hayes, David L. , Lohse, Christine M. , Wilson, Walter R. , Steckelberg, James M., Palraj, Raj , Khalid, Sana , Al-Saffar, Farah, Khalid, Sana , Baddour, Larry M. , Sohail, M Rizwan , Palraj, Raj

Circulation: Arrhythmia and Electrophysiology | December 12, 2014 | Volume: 8 | Issue: 1 | Pages: 137-144

10.1161/circep.114.002199 | PMID 25504648 Get It

Background— Prompt recognition of underlying cardiovascular implantable electronic device (CIED) infection in patients presenting with Staphylococcus aureus bacteremia (SAB) is critical for optimal management of these cases. The goal of this study was to identify clinical predictors of CIED infection in patients presenting with SAB and no signs of pocket infection. Methods and Results— All cases of SAB in CIED recipients at Mayo Clinic from 2001 to 2011 were retrospectively reviewed. We identified 131 patients with CIED who presented with SAB and had no clinical signs of device pocket infection. Forty-five (34%) of these patients had underlying CIED infection based on clinical or echocardiographic criteria. The presence of a permanent pacemaker rather than an implantable cardioverter-defibrillator (odds ratio, 3.90; 95% confidence interval, 1.65–9.23; P =0.002), >1 device-related procedure (odds ratio, 3.30; 95% confidence interval, 1.23–8.86; P =0.018), and duration of SAB ≥4 days (odds ratio, 5.54; 95% confidence interval, 3.32–13.23; P <0.001) were independently associated with an increased risk of CIED infection in a multivariable model. The area under the receiver operating characteristics curve for the multivariable model was 0.79, indicating a good discriminatory capacity to distinguish SAB patients with and without CIED infection. Conclusions— Among patients presenting with SAB and no signs of pocket infection, the risk of underlying CIED infection can be calculated based on the type of device, number of device-related procedures, and duration of SAB. We propose that patients without any of these high-risk features have a low risk of underlying CIED infection and may be monitored closely without immediate device extraction. Prospective studies are needed to validate this risk prediction model.
Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
Goldman, Jonathan H., Curtis, Kelly K., Hidalgo, Manuel , Calvo, Emiliano , Ryan, David P. , Wirth, Lori J. , Parikh, Asit, Partyka, James S., Faessel, Hélène M. , Gangolli, Esha, Stewart, S., Rosen, Lee S. , Eckhardt, Sabine , Borad, Mitesh J. , Bowles, Daniel W. , Calvo, Emiliano

Clinical Cancer Research | December 12, 2014 | Volume: 21 | Issue: 5 | Pages: 1002-1009

10.1158/1078-0432.ccr-14-1234 | PMID 25501576 Get It

Abstract Purpose: This first-in-human study assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of single and multiple doses of TAK-441, an investigational inhibitor of the Hedgehog signaling pathway. Experimental Design: Patients with advanced, solid tumors received daily oral TAK-441 (50–1,600 mg/day); daily dose was doubled in each subsequent cohort until the maximum tolerated/feasible dose (MTD/MFD) was reached. Blood was collected to evaluate TAK-441 plasma concentrations. Skin biopsies were obtained to evaluate suppression of the Hedgehog-regulated gene Gli1. Results: Thirty-four patients were enrolled (median age 59). The most common diagnoses were colorectal cancer (26%), basal cell carcinoma (BCC, 21%), and pancreatic cancer (9%). The MFD of 1,600 mg/day (based on tablet size and strength) was considered the MTD. Dose-limiting toxicities included muscle spasms and fatigue. Grade ≥3 treatment-emergent adverse events, regardless of causality, occurred in 15 patients (44%), of which hyponatremia (n = 4) and fatigue (n = 3) were most common. Oral absorption was fairly rapid; median Tmax was 2.0 to 4.0 hours after a single dose. Mean elimination half-life was 13.5 to 22.6 hours. Systemic exposure of TAK-441 based on the area under the plasma concentration–time curve was linear across the dose range. Gli1 expression in skin biopsies was strongly inhibited at all dose levels. Best response was partial response (1 patient with BCC) and stable disease (7 patients with various solid tumors). Conclusions: TAK-441 was generally well tolerated up to MFD of 1,600 mg/day, with preliminary antitumor activity. Further study of TAK-441 may be appropriate in populations selected for tumors with ligand-dependent or independent Hedgehog signaling. Clin Cancer Res; 21(5); 1002–9. ©2014 AACR.
Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis
Liu, Fei , Lagares, David , Choi, Kyoung Moo , Vrbanac, Vladimir , Probst, Clemens K. , Hiemer, Samantha E. , Sisson, Thomas H., Horowitz, Jeffrey C. , Rosas, Iván O. , Fredenburgh, Laura E. , Varelas, Xaralabos , Tager, Andrew M. , Tschumperlin, Daniel J. , Stopfer, Lauren, Stopfer, Lauren E. , Marinković, Аleksandar , Feghali‐Bostwick, Carol A. , Lagares, David , Varelas, Xaralabos

American Journal of Physiology-Lung Cellular and Molecular Physiology | December 12, 2014 | Volume: 308 | Issue: 4 | Pages: L344-L357

10.1152/ajplung.00300.2014 | PMID 25502501 Get It

Pathological fibrosis is driven by a feedback loop in which the fibrotic extracellular matrix is both a cause and consequence of fibroblast activation. However, the molecular mechanisms underlying this process remain poorly understood. Here we identify yes-associated protein (YAP) (homolog of drosophila Yki) and transcriptional coactivator with PDZ-binding motif (TAZ) (also known as Wwtr1), transcriptional effectors of the Hippo pathway, as key matrix stiffness-regulated coordinators of fibroblast activation and matrix synthesis. YAP and TAZ are prominently expressed in fibrotic but not healthy lung tissue, with particularly pronounced nuclear expression of TAZ in spindle-shaped fibroblastic cells. In culture, both YAP and TAZ accumulate in the nuclei of fibroblasts grown on pathologically stiff matrices but not physiologically compliant matrices. Knockdown of YAP and TAZ together in vitro attenuates key fibroblast functions, including matrix synthesis, contraction, and proliferation, and does so exclusively on pathologically stiff matrices. Profibrotic effects of YAP and TAZ operate, in part, through their transcriptional target plasminogen activator inhibitor-1, which is regulated by matrix stiffness independent of transforming growth factor-β signaling. Immortalized fibroblasts conditionally expressing active YAP or TAZ mutant proteins overcome soft matrix limitations on growth and promote fibrosis when adoptively transferred to the murine lung, demonstrating the ability of fibroblast YAP/TAZ activation to drive a profibrotic response in vivo. Together, these results identify YAP and TAZ as mechanoactivated coordinators of the matrix-driven feedback loop that amplifies and sustains fibrosis.